<DOC>
	<DOC>NCT01091103</DOC>
	<brief_summary>This study is being conducted to determine the effect of enzalutamide on the androgen signaling pathway in correlation with the anti-tumor effects of enzalutamide to identify potential predictors of response or resistance to therapy.</brief_summary>
	<brief_title>Determine the Effect of Enzalutamide (Formerly MDV3100) on the Androgen Signaling Pathway in Correlation With the Anti-tumor Effects of Enzalutamide to Identify Potential Predictors of Response or Resistance to Therapy</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Confirmed prostate cancer Presence of metastatic disease to the bone Ongoing androgen deprivation therapy Severe concurrent disease Metastases in the brain</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>